Navigation Links
Escalon(R) Subsidiary Escalon Digital Solutions Announces Release of Web-Based AXIS(TM) Image Management System

WAYNE, Pa., Oct. 23 /PRNewswire-FirstCall/ -- Escalon Medical Corp. (Nasdaq: ESMC) today announced that its Escalon Digital Solutions subsidiary released its Web-Based AXIS(TM) Image Management System.

AXIS(TM) seamlessly integrates ophthalmic diagnostic images from different sources into a single searchable database to facilitate ease of review, aid in identifying trends over time across multiple imaging modalities, and improve practice efficiency. AXIS(TM) offers several advantages including:

  • Easily manage all images from any diagnostic device, regardless of modality, manufacturer, or location... OCT, photography, visual fields, ultrasound, and more
  • Web-based interface provides access wherever needed - exam room, remote office, anywhere with Internet access
  • Seamlessly integrates patient records and schedules with EMR
  • Economical solution scaled specifically to client needs, from single-physician practices to large multi-facility institutions

"One of the key advantages of implementing AXIS(TM) is that the web-based nature of the program means access to images can be widely deployed, regardless of physical location, and done so without need for installation of additional software workstations," Matt Carnevale, Executive Vice-President, commented. "This makes scaling up a practice relatively quick and inexpensive."

Escalon Digital Solutions will be demonstrating the AXIS(TM) Image Management System at the upcoming AAO meeting in San Francisco, CA October 24-27, 2009.

Founded in 1987, the Company ( develops markets and distributes ophthalmic diagnostic, surgical and pharmaceutical products as well as vascular access devices. Drew Scientific, which operates as a separate business unit, provides instrumentation and consumables for the diagnosis and monitoring of medical disorders in the areas of diabetes, cardiovascular diseases and hematology, as well as veterinary hematology and blood chemistry. The Company seeks to utilize strategic partnerships to help finance its development programs and is also seeking acquisitions to further diversify its product line to achieve critical mass in sales and take better advantage of the Company's distribution capabilities, although such partnerships or acquisitions may not occur. The Company has headquarters in Wayne, Pennsylvania and operations in Long Island, New York, New Berlin, Wisconsin, Lawrence, Massachusetts, Dallas, Texas, Waterbury, Connecticut, Miami, Florida, Barrow-in-Furness, U.K. and Le Rheu, France.

Note: This press release contains statements that are considered forward-looking under the Private Securities Litigation Reform Act of 1995, including statements about the Company's future prospects. These statements are based on the Company's current expectations and are subject to a number of uncertainties and risks, and actual results may differ materially. The uncertainties and risks include whether the Company is able to:

  • implement its growth and marketing strategies, improve upon the operations of the Company business units, including the ability to make acquisitions and the integration of any acquisitions it may undertake, if any, of which there can be no assurance,
  • implement cost reductions,
  • generate cash,
  • identify, finance and enter into business relationships and acquisitions.

Other factors include uncertainties and risks related to:

  • new product development, commercialization, manufacturing and market acceptance of new products,
  • marketing acceptance of existing products in new markets,
  • research and development activities, including failure to demonstrate clinical efficacy,
  • delays by regulatory authorities, scientific and technical advances by the Company or third parties,
  • introduction of competitive products,
  • ability to reduce staffing and other costs and retain benefit of prior reductions
  • third party reimbursement and physician training, and
  • general economic conditions.

Further information about these and other relevant risks and uncertainties may be found in the Company's report on Form 10- K for year ended June 30, 2009, and its other filings with the Securities and Exchange Commission, all of which are available from the Securities and Exchange Commission as well as other sources.

SOURCE Escalon Medical Corp.

SOURCE Escalon Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Escalon(R) Subsidiary Sonomed Introduces New PacScan(TM) Plus A-Scan and Pachymeter
2. Escalon(R) Reports Fourth Quarter and Fiscal 2009 Results
3. Escalon(R) Announces Going Concern Qualification
4. Nyer Medical Group, Inc., Announces Agreements to Sell Certain Eaton Apothecary Assets to Walgreens and Sell Operating Subsidiarys Stock to Investors
5. Cantel Medicals Crosstex Subsidiary Launches New Specially Treated Face Mask Effective Against H1N1 Influenza
6. Subsidiary of Nova Biomedical Completes Acquisition of Assets of CCS Medicals Subsidiary, Sanvita, Inc.
7. New Places and People - Truphatek opens USA subsidiary
8. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Files Three Patent Applications
9. Cantel Medical Corp.s Crosstex Subsidiary Addresses School MRSA Concerns With SaniTyze(TM) Brand Hand Sanitizer and Sanitex(R) Surface Disinfecting Line of Products
10. Isis Announces $1.2 Million Award to Its Ibis Subsidiary to Expand Influenza Detection Capabilities and Enable Large-Scale Influenza Transmission Studies
11. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
Post Your Comments:
(Date:12/1/2015)... , December 1, 2015 ... new market research report "Nucleic Acid Labeling Market by ... Nick Translation, Random Primer, In Vitro Transcription, Reverse Transcription, ... published by MarketsandMarkets, The global market is expected to ... Million in 2015, growing at a CAGR of 8.65%. ...
(Date:12/1/2015)... , December 1, 2015 Russia ... clinical trials. 70% of new drugs registered in Europe ... Russia . --> Russia has always been ... of new drugs registered in Europe in 2015 ... --> Russia has always been a country ...
(Date:12/1/2015)... 2015 Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage ... announced today that the company will present at the LD ... at the Luxe Sunset Boulevard Hotel in Los ... Relmada Therapeutics, will present on Thursday, December 3, at 9:00 ... . Please register at least 10 minutes prior to the ...
Breaking Medicine Technology:
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... the 1980s we have seen vast improvements in scientific research and discoveries, leading ... strides, providing increased hope and relief to those affected by HIV/AIDS. Mediaplanet’s cross-platform ...
(Date:12/1/2015)... ... December 01, 2015 , ... The importance of volumetric ... the focus of numerous abstracts accepted for presentation here, at the 101st Annual ... abstracts highlight the use of Volpara Solutions’ quantitative breast imaging software tools for ...
(Date:12/1/2015)... ... December 01, 2015 , ... Next ... selected as a finalist in this year’s Fierce Innovation Awards: Healthcare Edition, an ... was recognized as a finalist in the category of Digital Solutions for its ...
(Date:12/1/2015)... ... , ... XTC Semifinals 2016 - CES, Las Vegas, Nevada - ... CES 2016, the world’s largest Consumer Electronic Show, where they will present to a ... of Pacific Investments Veronica Serra, and venture capitalist Tim Draper among many other top ...
(Date:12/1/2015)... ... 2015 , ... SonaCare Medical congratulates the University College London ... on November 18th. This prestigious award recognizes annually organizations that cultivate truly innovative ... medical landscape. , The UCLH team won the award for their innovative approach ...
Breaking Medicine News(10 mins):